Health
Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit – News-Medical.Net
Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response…
Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.
The phase III…
Continue Reading
